MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (176.72% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Canaccord GenuityReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015HC WainwrightLower Price TargetBuy$14.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015Chardan CapitalInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015LaidlawInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014Ascendiant Capital MarketsInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.32)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015($0.40)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aldeyra Therapeutics (NASDAQ:ALDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
DateHeadline
06/10/16 04:04 PMAldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/10/16 03:07 PMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 07:08 AMAldeyra Therapeutics, Inc. Announces Last Patient Dosed in Phase II Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 06/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
06/02/16 08:22 PMExclusive: Aldeyra CEO Todd Brady Talks Drug Potential, Cash & New Talent - Aldeyra Therapeutics Inc (NASDAQ: ALDX) is a micro-cap biotech company that specializes in the development of drugs for the treatment of immune and inflammatory diseases. Its most advanced drug is an eye drop treatment for Sjogren-Larsson Syndrome.
06/01/16 03:15 PMAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter Overallotment Option - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 06/01/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/29/16 11:25 AMWere Analysts Bullish Aldeyra Therapeutics Inc (NASDAQ:ALDX) This Week? - HNN - Were Analysts Bullish Aldeyra Therapeutics Inc (NASDAQ:ALDX) This Week?HNNOut of 5 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aldeyra Therapeutics Inc has been the topic of 2 analyst reports since August 13, 2015 according to ...and more »
05/27/16 11:43 AMEarnings Review and Stock Rundown for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ...and more »
05/27/16 11:43 AMGaps Down Stocks Update 1 – CSBR, SMT, ALDX, BRS, OVAS, TDW, PSTG - The company traded at $4.49 – 0.46 (9.29 pct). Aldeyra Therapeutics Inc (ALDX) had a gap down of (0.50) pts or -8.96 pct below its previous close of $5.58. The company traded at $5.03 – 0.55 (9.86 pct). Bristow Group Inc (BRS) had a gap down of (2.19 ...
05/27/16 11:43 AMALDX Prices Offering At $5.00/Share - (RTTNews.com) - Aldeyra Therapeutics Inc. ( ALDX) has offered to sell 2.4 million shares of its common stock to the public at a price of $5.00 each. The gross proceeds from the offering are expected to be $12.0 million. The company had cash of $23.0 ...
05/27/16 05:15 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -
05/26/16 10:46 AMAldeyra Therapeutics, Inc. (ALDX) Updated Price Targets - FTSE News - Aldeyra Therapeutics, Inc. (ALDX) Updated Price TargetsFTSE News08/13/2015 – Aldeyra Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock. 03/25/2015 – Chardan Capital began new coverage on Aldeyra Therapeutics, Inc. giving the company a ...
05/26/16 10:46 AMAldeyra Therapeutics (ALDX) Prices 2.4M Common Stock Offering at $5/Share - StreetInsider.com - Aldeyra Therapeutics (ALDX) Prices 2.4M Common Stock Offering at $5/ShareStreetInsider.comAldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced the pricing of an underwritten public offering of 2,400,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering are expected to be $12.0 ...Aldeyra Therapeutics Plans to Offer Shares in Underwritten Public Offering (NASDAQ:ALDX)Sonoran Weekly ReviewAldeyra Therapeutics Inc (NASDAQ:ALDX)'s Company Shares Decreased 8.37% After Low VolatilityWall Street Hints and NewsAldeyra Therapeutics, Inc. Proposes Public Offering of Common StockEIN News (press release)all 4 news articles »
05/26/16 10:46 AMAfter-Hours Stock Movers 05/25: (LGF) (PVH) (WSM) Higher; (PRGN) (PSTG) (ALDX) Lower (more...) - Revenue for the quarter came in at $791.2 million versus the consensus estimate of $740.67 million. Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10.2% LOWER; intends to offer and sell shares of its common stock in an underwritten public offering. The offering ...
05/26/16 08:07 AMAldeyra Therapeutics, Inc. Prices Public Offering of Common Stock - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 05/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/26/16 07:52 AM8:52 am Aldeyra Therapeutics prices 2.4 mln common stock offering at $5.00/share -
05/25/16 03:26 PMAldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 05/25/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/09/16 06:47 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or -
05/09/16 06:46 AMAldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 05/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/05/16 03:14 PMAldeyra Therapeutics Schedules Webcast and Conference Call for First Quarter 2016 Financial and Operating Updates - [Marketwired] - Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the first ...
03/31/16 06:33 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
03/30/16 08:44 AMEdited Transcript of ALDX earnings conference call or presentation 30-Mar-16 12:30pm GMT -
03/30/16 06:50 AMAldeyra Therapeutics Reports Full Year 2015 Financial Results - [at noodls] - LEXINGTON, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
03/09/16 02:52 PMAldeyra CEO Todd Brady Explains Why He Thinks Company Can Have 'Dramatic' Impact In Healthcare - Aldeyra Therapeutics Inc (NASDAQ: ALDX) is a small-cap biotech company that specializes in the development of drugs to treat immune and inflammatory diseases. Aldeyra’s most advanced drug is an eye drop treatment for Sjogren-Larsson Syndrome. Benzinga sat down with Aldeyra CEO Todd Brady to chat about the company’s outlook and what investors should expect going forward. Benzinga: Congratulations on the phase 2 study. The market looked like they really liked what they saw. The PR mentioned the ocular itching and tearing as the primary endpoints that you guys blew out of the water. How the redness endpoint was compared to the placebo? Todd Brady: Both drug and vehicle work to reduce redness. Redness is a particularly difficult endpoint to hit in this particular model, where patients are challenged with allergens. In fact, there may be some data out there, but I haven't seen any recently of a drug that's been able to reduce redness in a significant way in this model. So, we're not terribly concerned about that at this point. Gotcha. The other thing I saw from the PR was that two patients actually dropped out of the trial during treatment. I was wondering if you could possibly comment on that. Was it something to do with the trial? Or was it personal reasons? Or something else? No, the drug group had a higher rate than the vehicle group of stinging. And while all of it was transient, and the vast majority of it was very mild, there were two patients that dropped out of the drug arm because of stinging. But, as we said on the call yesterday, stinging is part of allergic conjunctivitis...the fact that drugs in these patients induced stinging is certainly very common. Phase 2 clinical data was expected for anterior uveitis treatment in Q2. Is there any update on when you might be able to give an exact date? Or is that something that you're not able to provide at this time? It's always hard to predict exactly when these trials will read out, just, given the complexities of them. In this case, there's three arms to the trial and many different endpoints that are being ...Full story available on Benzinga.com
02/29/16 10:55 AMAldeyra Therapeutics Surges 38%: Here's Why - Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a nano-cap biotechnology company, surged higher by more than 38 percent Monday morning after the company reported positive results from a Phase IIa clinical trial. Aldeyra Therapeutics reported that the results from a randomized, parallel-group Phase IIa clinical trial of topical ocular NS2 in subjects with induced allergic conjunctivitis ...Full story available on Benzinga.com
02/29/16 08:57 AMUPDATE 1-Aldeyra's eye drug found effective in mid-stage study - Feb 29 (Reuters) - Aldeyra Therapeutics Inc said its experimental eye drug proved to be more effective than a placebo in treating itching associated with allergic conjunctivitis in a mid-stage study.
02/29/16 07:24 AMAldeyra's eye drug found effective in mid-stage study - Feb 29 (Reuters) - Aldeyra Therapeutics Inc said its experimental eye drug proved to be more effective than a placebo in treating itching and tearing associated with allergic conjunctivitis in a...
02/09/16 07:30 AMAldeyra Therapeutics Appoints Mary Taylor, MPH as Senior Vice President, Regulatory Affairs - [GlobeNewswire] - LEXINGTON, Mass., Feb. 09, 2016-- Aldeyra Therapeutics, Inc., a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Mary E. Taylor, ...
02/02/16 03:08 PMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
01/11/16 07:58 AMAldeyra Therapeutics Appoints David J. Clark, M.D. as Chief Medical Officer - [at noodls] - LEXINGTON, Mass., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
01/11/16 06:01 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure -
12/16/15 07:58 AMAldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis - [at noodls] - LEXINGTON, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
12/10/15 11:00 AMIs Aldeyra Therapeutics Inc (ALDX) Going to Burn These Hedge Funds? -
12/08/15 12:17 PMALDEYRA THERAPEUTICS, INC. Financials -
11/24/15 07:43 AMAldeyra Therapeutics to Present at the 27th Annual Piper Jaffray Healthcare Conference - [at noodls] - LEXINGTON, Mass., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
11/13/15 10:06 AMALDEYRA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
11/12/15 06:56 AMAldeyra Therapeutics Reports Third Quarter and Year to Date 2015 Financial and Operating Results - [at noodls] - LEXINGTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
About Aldeyra Therapeutics

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.30
  • 50 Day Moving Average: $5.57
  • 200 Day Moving Average: $5.38
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $32.91M
  • Current Quarter EPS Consensus Estimate: $-1.76 EPS
Additional Links:
Aldeyra Therapeutics (NASDAQ:ALDX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha